Rocket Pharmaceuticals, Inc.
$3.47
The Read: Rocket Pharmaceuticals' stock surged over 50% after narrowing losses and beating EPS estimates alleviated cash runway fears, then dipped 7% post-FDA approval due to sell-the-news, rose 2% on a capital-raising follow-on offering, but fell 21% after Q1 earnings met expectations with no new catalysts despite a $180M voucher sale.
Price
Overlays
Panel
RCKT
Hover to view data
No Data